In patients with CRC receiving adenovirus (coding for carcinoembryonic antigen, CEA), over half the patients had NAbs at baseline yet, despite increasing levels, there was evidence of an antigen specific immune response to treatment [4], indicating that NAb levels may not be a barrier to successful therapy. This evidence concerns the gene CEACAM5 and colorectal carcinoma.